Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenue, net $ 8,189 $ 8,057 $ 23,506 $ 24,006
Cost of revenue 3,457 3,620 10,286 10,205
Gross profit 4,732 4,437 13,220 13,801
Operating expenses:        
Sales and marketing 2,236 2,244 6,987 6,931
Research and development 191 322 626 1,178
General and administrative 2,767 2,566 8,636 7,389
Transition expense 236 897
Gain on DiamiR transaction (235)
Acquisition related amortization expense 318 894 953 2,682
Change in fair value of contingent consideration (311) (57)
Total operating expenses 5,512 6,262 16,891 18,785
Operating loss from continuing operations (780) (1,825) (3,671) (4,984)
Interest accretion expense (38) (106) (123) (375)
Related party interest (151) (372)
Note payable interest (230) (620)
Other income (expense), net (217) 49 (20) (248)
Loss from continuing operations before tax (1,265) (2,033) (4,434) (5,979)
(Benefit) provision for income taxes (11) (714) 24 (684)
Loss from continuing operations (1,254) (1,319) (4,458) (5,295)
Loss from discontinued operations, net of tax (12,954) (2,242) (15,936) (5,919)
Net loss $ (14,208) $ (3,561) $ (20,394) $ (11,214)
Basic and diluted loss per share of common stock:        
From continuing operations $ (0.30) $ (0.32) $ (1.05) $ (1.29)
From discontinued operations (3.05) (0.53) (3.77) (1.43)
Net loss per basic and diluted share of common stock $ (3.35) $ (0.85) $ (4.82) $ (2.72)
Weighted average number of common shares and common share equivalents outstanding:        
Basic 4,242 4,165 4,227 4,119
Diluted 4,242 4,165 4,227 4,119